10x Genomics CEO swaps 31,000 shares for fund shares

Available on EDGAR 11/13/2026 - 04:54 PM EST Accepted by SEC EDGAR 11/13/2026 - 04:53 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Serge Saxonov reported sale transactions in this Form 4 filing. 10x Genomics, Inc. Chief Executive Officer and director Serge Saxonov contributed 31,000 directly held Class A common shares to an exchange fund on November 10, 2026, in exchange for fund shares. The shares were valued at $62.90 each to determine the number of fund shares issuable. Saxonov reported direct ownership of 1,019,249 shares afterward. Other reported indirect holdings were in the Andromeda Trust, Y/S Descendants' Trust and Y/S Pot Trust.

Insider Trade Summary

Net Seller: 31,000 shares

Net Sell 1 txn

Insider Saxonov Serge

Role Chief Executive Officer

Sold 31,000 shs ($1.95M)

Share of Position Sold 3.0%

Type	Security	Shares	Price	Value
Sale	Class A Common Stock F1	31,000	$62.90	$1.95M
Holding	Class A Common Stock F2	--	--	--
Holding	Class A Common Stock F3	--	--	--
Holding	Class A Common Stock F4	--	--	--

Holdings After Transaction: Class A Common Stock — 1,019,249 shares (Direct); Class A Common Stock — 284,921 shares (Indirect, See footnote)

Holdings Before and After: Class A Common Stock, 1,050,249 to 1,019,249 shares (Direct)

Footnotes (4)

1. F1. The Reporting Person contributed the shares to an exchange fund in exchange for shares of the exchange fund. The shares were valued at $62.90 per share for the purpose of determining the number of shares of the exchange fund issuable to the Reporting Person.
2. F2. The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee.
3. F3. The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.
4. F4. The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee.

Key Figures

Shares contributed: 31,000 shares Valuation per share: $62.90 per share Direct shares following transaction: 1,019,249 shares

3 metrics

Shares contributed 31,000 shares Class A common shares contributed to an exchange fund on November 10, 2026

Valuation per share $62.90 per share Used to determine the number of exchange-fund shares issuable

Direct shares following transaction 1,019,249 shares Saxonov's reported direct ownership after the transaction

Key Terms

exchange fund

1 terms

exchange fund financial

"contributed the shares to an exchange fund"

An exchange fund is a pooled investment vehicle where holders of a single, highly appreciated stock swap their shares for pro rata interests in a diversified basket, allowing them to reduce concentration risk without immediately selling and triggering a large capital gains tax. It matters to investors because it provides instant diversification and potential tax deferral—like trading one oversized slice of pie for many smaller slices—though it usually carries fees, a multi‑year lockup and less control over exact timing of liquidity.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did 10x Genomics CEO Serge Saxonov do with TXG shares?

Serge Saxonov contributed 31,000 directly held Class A common shares to an exchange fund on November 10, 2026, in exchange for fund shares. The shares were valued at $62.90 each to determine the number of exchange-fund shares issuable.

How many TXG shares did Serge Saxonov hold directly after the exchange?

Saxonov reported direct ownership of 1,019,249 shares after the exchange.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Saxonov Serge

(Last) (First) (Middle)

10X GENOMICS, INC.

6230 STONERIDGE MALL ROAD

(Street)

PLEASANTON CALIFORNIA 94588

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
10x Genomics, Inc. [ TXG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	11/10/2026		S(1)		31,000	D	$62.9(1)	1,019,249	D
Class A Common Stock								27	I	See footnote(2)
Class A Common Stock								213,250	I	See footnote(3)
Class A Common Stock								71,644	I	See footnote(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person contributed the shares to an exchange fund in exchange for shares of the exchange fund. The shares were valued at $62.90 per share for the purpose of determining the number of shares of the exchange fund issuable to the Reporting Person.

2. The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee.

3. The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.

4. The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee.

	/s/ Randy Wu, as Attorney-in-Fact for Serge Saxonov	11/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)